BIOTECHNOLOGY AND CANCER TREATMENT WITH CLAY SIEGALL

In January 2013, an announcement by Mirna Therapeutics, a Texas-based company founded in 2007, that focuses on macroRNA in therapeutics, confirmed that Seattle Genetics co-founder, Dr. Clay Siegall, who is also the Chairman of the Board of Directors, and the current Chief Executive Officer, would be appointed as a member of the board of directors, as an outside Director. Mirna Therapeutics currently focus on cancer research and Dr. Seagull has a background in the subject.

Seattle Genetics is a leading biotechnology company that works on developing both Clinical and Pre-clinical products. The company is mainly based on research, scientific innovations, and drug development procedures. On drug development practises, the company focuses on developing ADC technology, which reduces toxic effects of chemotherapy and enhances antitumor activity. The ADC technology is divided into different programs. SGN-CD33A is used for acute myeloid leukemia, whereas SGN-CD 19A is used for non-Hodgkin lymphoma. ADCETRIS therapy, used for Lymphoma patients has treated over 15000 patients worldwide. SEA-CD40 is scheduled to be used for solid tumours and was the first engineered Antibody to be developed using SEA technology.

Dr. Clay Siegall, the current president and C.E.O of Mirna Therapeutics said the company is excited to work with Dr. Seagull on the Board of Directors, with his expertise in cancer research. He also said they expect Dr. Siegall to assist through guiding them in advancements and development of their micro-based therapeutics. Seattle Genetics was co-founded by Dr. Siegall in the year 1998. Mr. Clay acquired his Bachelors in science Zoology and later went on to pursue his Ph.D. in Genetics at George Washington University. He worked for the National Cancer Institute, National Institute of Health, as well as Bristol- Myers Squibb Pharmaceutical Research Institute before finally co- founding Seattle Genetics.

His has vast expertise and experience in leading Seattle Genetics Company to successfully create Antibody-based therapies for Cancer patients whose medical needs had been sidelined. Read More:

http://newschoolmagazine.com/index.php/category/clay-siegall/

Seattle Genetics Continues To Advance Cancer Therapies

Biotech industry pioneer Seattle Genetics has been drawn in to advancing anti-body based therapies for the treatment of cancer for more than ten years.

Under the direction of President, Chief Executive Officer and Chairman of the Board, Clay Siegall, the company has built a diverse channel of antibody-based cancer therapies through its proprietary, industry leading technology.

Siegall, who cofounded Seattle Genetics in 1998, has a Ph.D. in genetics from George Washington University. He is an author of more than 70 publications and holds 15 patents.

The company’s ADCETRIS (brentuximab vedotin) is a CD30-targeted antibody-drug conjugates (ADC) available in sixty countries and is being evaluated in more than seventy ongoing clinical trials.

ADCs are aimed at pinpointing and destroying the cancer cells only while sparing non-targeted cells and saving the healthy cells.

ADCs also reduce many of the toxic results of conventional chemotherapy while improving antitumor activity.

Seattle Genetics is also advancing vadastuximab talirine which is an ADC expected to advance into a phase 3 trial for acute myeloid leukemia this year.

The company has multiple strategic licenses for its ADC technology with biotechnology and pharmaceutical companies that include AbbVie, Agensys, Bayer, Pfizer and others.

Seattle Genetics predicts 2016 total revenues will extend from $390 to $430 million and revenues from collaboration and license agreements will be in the $75 million to $90 million range.

The company said more than twenty five other ADCs are under development and may become the basis of additional revenue.

According to Siegall the company is in a favorable position to carry on with its aggressive research, scientific and business-related objectives.

Siegall previously worked for the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health. His board memberships include Alder BioPharmaceuticals and Mirna Therapeutics.

Read More Here

http://www.seattlepi.com/business/article/A-moment-with-Clay-Siegall-President-and-CEO-1168583.php

http://www.xconomy.com/author/csiegall/